MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
Summary
The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for faster and more effective drug development. “HUB’s advanced technology, combined with our innovations in 3D cell culture and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of organoids to understand the impact of drug response earlier in the development process.” HUB possesses the foundational patent portfolio on organoids and a robust service offering ranging from new model generation to assay development and high-throughput screening, enhancing the Life Science business of Merck KGaA, Darmstadt, Germanys offering of cell culture tools to academia, biotech, and pharma customers. About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email.